Guideline for the diagnosis and management of myelofibrosis. - Wikidata - awgldk - TriplyDB

Guideline for the diagnosis and management of myelofibrosis.

Guideline for the diagnosis and management of myelofibrosis.

http://www.wikidata.org/entity/Q50495964

about

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies Guidelines for the management of myeloproliferative neoplasms Clinical potential of pacritinib in the treatment of myelofibrosis Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis Practical management of patients with myelofibrosis receiving ruxolitinib.Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.Safety considerations when treating myelofibrosis.Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.A case of mistaken identity: When lupus masquerades as primary myelofibrosis.Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090 Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.How common are myeloproliferative neoplasms? A systematic review and meta-analysis.Acute duodenal ischemia and periampullary intramural hematoma after an uneventful endoscopic retrograde cholangiopancreatography in a patient with primary myelofibrosis.Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis.A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence.Epigenetics in Myeloproliferative Neoplasms.Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study.Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms.Steroid-resistant autoimmune myelofibrosis in a patient with autoimmune hepatitis and Evans syndrome complicated with increased expression of TGF-β in the bone marrow: a case report.Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage.Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.Pathology reporting of bone marrow biopsy in myelofibrosis; application of the Delphi consensus process to the development of a standardised diagnostic report

P2860

Q26744113-EE05B6B8-9798-478A-A8BF-830AA543C711 Q26778326-2C5DD9E0-6B7E-4B5B-B478-AF58D898C0BD Q26796450-CB71F0C6-5C6B-4D82-98FB-833BD7C30A43 Q26996258-EAC45BAE-AD86-4296-80B7-0AF6B17CD473 Q33410649-97058132-38BC-408E-820B-53086FDCF27D Q33411755-1C205BC8-9B02-4503-B9E7-55E21BF59736 Q33420358-36D8109F-7B5F-4FD7-9477-D00B31D43C21 Q33432285-BDBD00EC-9084-4116-871F-2B00F2B0D608 Q33441917-AB4E77DA-7120-4131-8071-869AE74C5963 Q36871360-47121457-42A2-4B58-816F-8E1CB482144D Q36874807-022471EA-9E0F-4878-9B4A-971D02F065FC Q37168132-D54CE1DE-FCE5-4285-A7A0-8CBF48F4A7F5 Q37168138-694445A6-A774-4A16-BC2A-AF95E44CE1B1 Q37250169-C25229FA-B5FD-4CDE-A6FF-E10455061F76 Q38065306-DC4DF232-BEF4-4579-8D6F-316BC48FFC85 Q38223791-E5D063BC-4B4E-4263-B2FF-950C383D30BE Q38437236-3FD34BA6-3096-4F24-9DF8-04F6BB29B052 Q38570614-339EBCD5-87D5-4526-BA6E-BDEC913C2E9F Q38764516-D391B06F-91DD-4F6B-8FFC-9E8ED3377FB3 Q38798560-7F7B5403-E280-4B69-A458-3D9F88A6FF81 Q38945717-EF47CA20-3DAF-4BF4-98BF-72A9B93E9D5B Q39414554-2C32B488-8898-498D-B41E-CDD9452F4E0C Q39554738-49BFBA78-C3DB-4080-801D-D2B43C960E96 Q40587986-D1CEC6A4-E6DE-4FA0-8A5D-CECDCE605CFA Q45236578-CC4E033E-4862-4D07-A938-46F97B72D41A Q46110570-3F788CEC-87B0-4389-B3DB-20B2DC25A255 Q47740647-33BEA2F3-00A4-4A57-9881-CD26E8B33F90 Q48144615-89F73741-5211-4526-B9CF-7F0169E54836 Q50453985-3ABA8B6C-EE04-46F6-BFFA-29957B5764C9 Q50454348-1CCAFE6D-1BFB-427C-895B-2D2F9BD4C170 Q50890627-E1C0B08E-A33D-4DF8-BA1A-A4CB65932319 Q51664942-914838DF-9682-42B7-B2FA-63D3639F53DE Q57786924-BCC68CE1-8F90-4E9B-8DD9-52DB02594BDE

P2860

Guideline for the diagnosis and management of myelofibrosis.

http://www.wikidata.org/entity/Q50495964

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Guideline for the diagnosis and management of myelofibrosis.

@en

Guideline for the diagnosis and management of myelofibrosis.

@nl

type

label

Guideline for the diagnosis and management of myelofibrosis.

@en

Guideline for the diagnosis and management of myelofibrosis.

@nl

prefLabel

Guideline for the diagnosis and management of myelofibrosis.

@en

Guideline for the diagnosis and management of myelofibrosis.

@nl

P1433

Q50495964-E925517D-4308-448E-910D-845A8D817E75

P1476

Q50495964-91FDAAFC-7E20-4100-9588-5CA72432876D

P2093

Q50495964-193FCB57-EB82-45FF-9413-4067F86F8EA7

Q50495964-57A9AAFA-1103-48FA-B031-69A182EF3B6B

Q50495964-685631F4-F45F-4EDC-8B73-629DC0FDC4BF

Q50495964-6C58E20F-50F2-4E19-BF06-EC3F00D0F3B6

Q50495964-786C46C2-74D0-4921-8E9A-E4C37E24945C

Q50495964-7F859285-1898-4243-A93B-6B5A231D38DA

Q50495964-95AA6C42-8DC6-45DE-9F40-4F98BE818563

Q50495964-9AE24257-C0B0-438B-9C81-336B70D1636C

Q50495964-C846ABED-0BF5-4DD2-9249-74608D2EC951

Q50495964-D5F9A627-B21B-446B-B636-C318EC0F1DAB

P2860

Q50495964-072F207C-834F-4CD5-B361-AF04FFB0FAA4

Q50495964-10416D6A-777B-41EF-B4E5-FB280D010A81

Q50495964-10766EBF-6F0F-4DF8-B7BD-CCD675FC5231

Q50495964-117876D4-44F9-4D8B-A099-1125EA8DEB72

Q50495964-1551D3D6-383D-4CB5-88C1-40BC882D90C9

Q50495964-16725576-647C-4871-9206-3F83EF3A7E30

Q50495964-23BE97B1-C163-48A4-968B-A5B0A116EF1F

Q50495964-25286985-825B-4FAB-BF49-93892B9FBB32

Q50495964-29BA1034-97F4-47E6-883C-AB919638ADAE

Q50495964-2D56270B-D5B4-4272-9861-3B59320530F0

P304

Q50495964-B9A8375D-24C3-4758-9172-F2C328AC8B1C

P31

Q50495964-FC06B90F-BC44-4AA6-A0C9-9B6D4D55765D

P356

Q50495964-04ACA607-089D-44BF-B000-B858CCAF04E5

P407

Q50495964-908EA048-D3C1-4CB6-9009-AA2449DD4642

P433

Q50495964-07C5B659-DC1B-4AD8-BFB6-6AF9FCB6F817

P478

Q50495964-011CBE56-2F22-4B84-91C5-AAD85B553163

P50

Q50495964-333FB41D-6797-4073-A92F-57A87AF86EF8

Q50495964-74E2D1BF-F7A2-4DA4-844E-CBB22770DDF3

Q50495964-8FCB50FA-BD91-4394-8CFD-407E9708183D

Q50495964-DDBFB360-C79E-4D06-80E3-6D42A5DFC801

P577

Q50495964-C842E8CE-732D-44A1-B490-0EA150118A2D

P5875

Q50495964-845C0249-6C81-47A1-B0E0-DA605275A0E5

P698

Q50495964-E721C704-383A-41BD-9489-6C0198156DE0

P356

J.1365-2141.2012.09179.X

P1433

British Journal of Haematology

P1476

Guideline for the diagnosis and management of myelofibrosis

@en

P2093

Andrew Duncombe

http://www.w3.org/2001/XMLSchema#string

Bridget Wilkins

http://www.w3.org/2001/XMLSchema#string

Claire N Harrison

http://www.w3.org/2001/XMLSchema#string

Eibhlean Conneally

http://www.w3.org/2001/XMLSchema#string

Georgina W Hall

http://www.w3.org/2001/XMLSchema#string

John T Reilly

http://www.w3.org/2001/XMLSchema#string

Mary Frances McMullin

http://www.w3.org/2001/XMLSchema#string

N George Michaeel

http://www.w3.org/2001/XMLSchema#string

Nauman Butt

http://www.w3.org/2001/XMLSchema#string

Philip A Beer

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

Guideline for investigation and management of adults and children presenting with a thrombocytosis

Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia.

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.

Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase.

P304

453-471

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2012.09179.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

158

http://www.w3.org/2001/XMLSchema#string

P50

Anthony R Green

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225085454

http://www.w3.org/2001/XMLSchema#string

P698

22651893

http://www.w3.org/2001/XMLSchema#string